On August 13, 2025, Dogwood Therapeutics, Inc. announced financial results for the second quarter of 2025 and provided a business update. Enrollment in the Phase 2b trial of Halneuron for the treatment of Chemotherapy Induced Neuropathic Pain (CINP) has reached 52 patients. An interim data readout is expected in the fourth quarter of 2025. For the first 38 patients completing the trial there was a very low discontinuation rate (5.8%), suggesting that Halneuron and placebo treatment have both been generally well tolerated. Dogwood exited the second quarter of 2025 with $13.4 million, which we estimate will fund operations through the first quarter of 2026.
